Johnson & Johnson Innovation – JJDC

Activity in this selectioneuclidean-capital-095b3c13

By stage

Series B2

Undisclosed2

Seed1

Series C+1

Biotech5

Healthtech1

United States5

United Kingdom1

6 in this selection

Jun 23

Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases

$47MSeed+

Role not disclosed

Jun 10

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B

Role not disclosed

Jun 4

Develops minimally invasive eShunt System to treat communicating hydrocephalus and other neurological diseases

$85MSeries C

Role not disclosed

Jan 27

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosed

Role not disclosed

Jan 22

Builds pro-resolution platform for target ID and drug discovery for inflammatory diseases

Role not disclosed

Jan 8

Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...

$107MSeries B

Role not disclosed